Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Carrasco-Sánchez, Francisco Javier; Carretero-Anibarro, Enrique; Gargallo, Manuel; Gómez‐Huelgas, Ricardo; Merino-Torres, Juan Francisco; Orozco‐Beltrán, Domingo; Corrales, Pedro José Pinés; Quintero, Manuel Antonio Ruiz

doi:10.1016/j.endien.2022.02.008

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent Summary from Expert consensus on effectiveness and safety of DPP4 inhibitors in the treatment of patients with diabetes and COVID-19 [ 159 ], it was concluded that the use of the inhibitors may present a specific benefit in reducing mortality, particularly in in-hospital use, reducing admission to intensive care units and the need for mechanical ventilation and most importantly, the use of DPP4 inhibitors appears to be safe in patients with COVID-19. Altogether these data indicate that DPP4 inhibitors have a potential therapeutic value in the multi-organ injury caused by COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

et al. 2022

View full text Add to dashboard Cite

DPP4/CD26 is a single-pass transmembrane protein with multiple functions on glycemic control, cell migration and proliferation, and the immune system, among others. It has recently acquired an especial relevance due to the possibility to act as a receptor or co-receptor for SARS-CoV-2, as it has been already demonstrated for other coronaviruses. In this review, we analyze the evidence for the role of DPP4 on COVID-19 risk and clinical outcome, and its contribution to COVID-19 physiopathology. Due to the pathogenetic links between COVID-19 and diabetes mellitus and the hyperinflammatory response, with the hallmark cytokine storm developed very often during the disease, we dive deep into the functions of DPP4 on carbohydrate metabolism and immune system regulation. We show that the broad spectrum of functions regulated by DPP4 is performed both as a protease enzyme, as well as an interacting partner of other molecules on the cell surface. In addition, we provide an update of the DPP4 inhibitors approved by the EMA and/or the FDA, together with the newfangled approval of generic drugs (in 2021 and 2022). This review will also cover the effects of DPP4 inhibitors (i.e., gliptins) on the progression of SARS-CoV-2 infection, showing the role of DPP4 in this disturbing disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

et al. 2022

View full text Add to dashboard Cite

show abstract

Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m⁶₂A and CD) regulations on patients with cancer and healthy individuals

Zhang

et al. 2023

Int J Oncol

View full text Add to dashboard Cite

The worldwide COVID-19 pandemic was brought on by a new coronavirus (SARS Cov-2). A marker/receptor called Dipeptidyl peptidase 4/CD26(DPP4/CD26) may be crucial in determining susceptibility to tumors and coronaviruses. However, the regulation of DPP4 in COVID-invaded cancer patients and its role on small molecule compounds remain unclear. The present study used the Human Protein Atlas, Monaco, and Schmiedel databases to analyze the expression of DPP4 in human tissues and immune cells. The association between DPP4 expression and survival in various tumor tissues was compared using GEPIA 2. The DNMIVD database was used to analyze the correlation between DPP4 expression and promoter methylation in various tumors. On the cBioPortal network, the frequency of DPP4 DNA mutations in various cancers was analyzed. The correlation between DPP4 expression and immunomodulators was analyzed by TISIDB database. The inhibitory effects of cordycepin (CD), N6, N6-dimethyladenosine (m 6 2 A) and adenosine (AD) on DPP4 in cancer cells were evaluated. DPP4 was mainly expressed in endocrine tissue, followed by gastrointestinal tract, female tissue (mainly in placenta), male tissue (mainly in prostate and seminal vesicle), proximal digestive tract, kidney, bladder, liver, gallbladder and respiratory system. In immune cells, DPP4 mRNA was mainly expressed in T cells, and its expression was upregulated in esophageal carcinoma, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma and thymoma. However, it was downregulated in breast invasive carcinoma, kidney chromophobe, lung squamous cell carcinoma and skin cutaneous melanoma. Thus, DPP4 is involved in viral invasion in most types of cancer. The expression of DPP4 could be inhibited by CD, m 6 2 A and AD in different tumor cells. Moreover, CD significantly inhibited the formation of GFP-positive syncytial cells. In vivo experiments with AD injection further showed that AD significantly inhibited lymphocyte activating factor 3 expression. These drugs may have potential to treat COVID-19 by targeting DPP4. Thus, DPP4 may be medically significant for SARS-CoV-2-infected cancer patients, providing prospective novel targets and concepts for the creation of drugs against COVID-19.

show abstract

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Cited by 2 publications

References 16 publications

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m⁶₂A and CD) regulations on patients with cancer and healthy individuals

Contact Info

Product

Resources

About

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Cited by 2 publications

References 16 publications

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals

Contact Info

Product

Resources

About

Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m⁶₂A and CD) regulations on patients with cancer and healthy individuals